Clinical trials: Bronchial Carcinoma
Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
- Trial name
- NCT05544929
- Testing
- KFA115, pembrolizumab
- Where
- 18 sites in United States, Canada and 10 more
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer
Combination Chemotherapy Followed by Surgery in Treating Patients With Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug with surgery may kill more tumor cells.
- Trial name
- NCT00003231
- Testing
- cisplatin, docetaxel, surgical procedure
- Where
- 9 sites in Switzerland
- Volunteers
- 40 people
- Sponsor
- Swiss Cancer Institute
Neoplasms, Non-small-cell Lung Cancer
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
The purpose of this study is to learn about the: safety (the effect of the study medicine on the participant's body), effects of the study medicine alone or in combination with sasanlimab - the best amount of the study medicine.
- Conditions
- Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma
- Trial name
- NCT06546553
- Testing
- PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo)
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Small-cell Lung Cancer
Watchful Observation of Patients With LD-SCLC Instead of the PCI
Prophylactic cranial irradiation (PCI) is a current standard of care after confirmed response to radical chemoradiotherapy for limited disease small cell lung cancer (LD-SCLC).
- Trial name
- PCILESS (NCT04168281)
- Testing
- Magnetic resonance imaging (MRI)
- Where
- Poland
- Volunteers
- 80 people
- Sponsor
- Sergiusz Nawrocki
Lung Cancer Non-Small Cell Cancer (NSCLC)
Cross-sectorial Rehabilitation of Patients with Lung Cancer
Four thousand seven hundred patients are diagnosed with lung cancer in Denmark every year. Even though cigarette smoking has declined for decades a decline in lung cancer incidence is still at least a decade away.
- Trial name
- NCT06705465
- Testing
- video conference
- Where
- Denmark
- Volunteers
- 130 people
- Sponsor
- Camilla Balle
Lung Cancer
Combination Chemotherapy Followed by Radiation Therapy With or Without Paclitaxel in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00039039
- Testing
- carboplatin, chemotherapy, cisplatin
- Where
- 37 sites in Italy
- Volunteers
- 300 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Carcinoma, Non-Small-Cell Lung
A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC
This was a single-arm, open label, multicenter phase II, study of dabrafenib in combination with trametinib in Chinese participants with BRAF V600E mutation positive, stage IV NSCLC (American joint committee on cancer staging 8th…
- Trial name
- NCT04452877
- Testing
- Dabrafenib, Trametinib
- Where
- 8 sites in China
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Renal Cell, Carcinoma, Non-Small-Cell Lung
A Study of Oncobax®-AK in Patients With Advanced Solid Tumors
Akkermansia muciniphila is a naturally occurring bacterium found in the healthy human gastrointestinal tract. Analysis of the gut microbiota of NSCLC or RCC patients shows that the presence of Akkermansia is associated with the…
- Trial name
- NCT05865730
- Testing
- Live Bacterial Product - Akkermansia muciniphila
- Where
- 4 sites in Belgium, France
- Volunteers
- 122 people
- Sponsor
- EverImmune
Extensive-stage Small Cell Lung Cancer (SCLC)
YSQTG Combined With Immuno-chemotherapy for Extensive-Stage Small Cell Lung Cancer
Globally, lung cancer stands as the foremost cause of cancer-related mortality. Among its subtypes, small cell lung cancer (SCLC) represents an exceptionally aggressive malignancy, accounting for approximately 15-20% of all lung…
- Trial name
- NCT07390565
- Testing
- Yishen Qutong Granules, Yishen Qutong Simulant Granules
- Where
- China
- Volunteers
- 308 people
- Sponsor
- LI FENG
Thoracic Tumors, Non-small Cell Lung Cancer
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor Anvumetostat administered in combination with other therapies in adult participants with metastatic…
- Trial name
- NCT06333951
- Testing
- Anvumetostat, Carboplatin, Paclitaxel
- Where
- 83 sites in United States, Argentina and 18 more
- Volunteers
- 49 people
- Sponsor
- Amgen
Limited-stage Small Cell Lung Cancer (LS-SCLC)
Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy
This study aims to explore the efficacy and safety of immunotherapy (PD-L1 inhibitor) maintenance following high-dose hyperfractionated simultaneous integrated boost radiotherapy concurrent chemotherapy in patients with…
- Trial name
- NCT06869239
- Testing
- Etoposide + cisplatin/carboplatin, Thoracic radiotherapy, Prophylactic cranial irradiation (PCI)
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Peking University Cancer Hospital & Institute
Lung Cancer
Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy in treating patients with non-small cell lung cancer that cannot be surgically…
- Trial name
- NCT00002577
- Testing
- radiation therapy
- Where
- 242 sites in United States, Canada
- Volunteers
- 36 people
- Sponsor
- Radiation Therapy Oncology Group
Non-Small Cell Lung Cancer (NSCLC), Rehabilitation
Digital Rehabilitation With Wearable Monitors for Sequential Lung Cancer Resection
This is a prospective, open-label, parallel-group, 1:1 randomized controlled trial designed to evaluate whether a digital rehabilitation program integrated with wireless wearable continuous monitoring devices can shorten the time…
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Rehabilitation, Thoracic Surgery
- Trial name
- WEAR-MPLC (NCT07797075)
- Testing
- Wireless Wearable Vital Sign and Activity Monitor, Digital Pulmonary Rehabilitation Program, Standard ERAS Perioperative and Rehabilitation Care
- Where
- China
- Volunteers
- 222 people
- Sponsor
- West China Hospital
Carcinoma, Non-Small-Cell Lung, Immunotherapy
Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH)
This study was a French multicentric cross-sectional study retrospectively of 108 consecutive advanced NSCLC patients with a PD-L1 TPS ≥50% and without EGFR/ALK aberrations treated by pembrolizumab in first line.
- Trial name
- PEMBREIZH (NCT05321212)
- Where
- 2 sites in France
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- University Hospital, Brest
Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer
Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases
The patients carrying a complicated primary lung cancer brain metastases die in less than 3 months of delay disease in the absence of treatment.
- Conditions
- Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer, Adenocarcinoma of Lung Metastatic to Brain, Cerebral Metastases
- Trial name
- METAL2 (NCT02162537)
- Testing
- Cisplatin, Pemetrexed, Bevacizumab
- Where
- 41 sites in France
- Volunteers
- 95 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Lung Cancer
Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as hydroxychloroquine, carboplatin, and paclitaxel and work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00728845
- Testing
- bevacizumab, carboplatin, hydroxychloroquine
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Lung Cancer
Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer
The purpose of this study is to determine the safety and the maximum tolerated dose (MTD) of GRN163L when administered in combination with a standard paclitaxel/carboplatin regimen to patients with advanced or metastatic…
- Trial name
- NCT00510445
- Testing
- Imetelstat Sodium (GRN163L)
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Geron Corporation
Carcinoma, Non-Small-Cell Lung, Mesothelioma
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
This study will determine the maximum-tolerated dose (MTD) for oral bosutinib when used in combination with pemetrexed. The MTD is the highest dose of bosutinib with pemetrexed that can be given without causing severe side…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Mesothelioma, Bladder Cancer, Ovarian Cancer
- Trial name
- NCT03023319
- Testing
- Bosutinib, Pemetrexed
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Nagla Abdel Karim
Carcinoma, Non-Small-Cell Lung
The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
The standard treatment for non-small cell lung cancer, stage IV or IIIB malignant pleural effusion is chemotherapy. The decision to use a regimen is currently determined by toxicity or by physician's preference.
- Trial name
- NCT00215930
- Testing
- Vinorelbine, Docetaxel, Gemcitabine
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative
This phase II/III trial compares the addition of radiation therapy to the usual treatment (immunotherapy with or without chemotherapy) versus (vs.) usual treatment alone in treating patients with non-small cell lung cancer that…
- Conditions
- Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8
- Trial name
- NCT04929041
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 169 sites in United States
- Volunteers
- 427 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.